32 citations
,
October 2004 in “Pharmacotherapy” In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.
This study suggests that bioactives like Curcumin, Quercetin, and "Tulsi" may relieve chemotherapy-induced adverse drug reactions in cancer patients, potentially reducing resistance and recurrence.
38 citations
,
February 2006 in “British Journal of Clinical Pharmacology” This study found that combining data from different databases provided a more comprehensive estimate of serious adverse drug reactions in a French university hospital, highlighting the limitations of current ADR reporting methods.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
